Abstract
Non-invasive and invasive diagnostic methods, which are not readily available in Sudan, are used to guide HBV treatment. Africa adopted the TREAT-B as a straightforward score in 2018 to identify patients in need of anti-HBV treatment.
 Objective: To compare the diagnostic accuracy of the TREAT-B score to the standard scores EASL and AASLD in HBV patients.
 Methods: At Ibn Sina Specialized Hospital, 108 HBV patients were enrolled in an analytical cross-sectional study (January- October 2019). Data was collected using an interviewer-administered questionnaire and analyzed using SPSS.
 Results: Eight patients (7.4%) were eligible for therapy under the AASLD recommendations, 18 patients (16.7%) were suitable under the EASL guidelines, and twenty-seven patients (25%) were eligible under the TREAT-B guidelines. According to the Wald statistic, the AUROC of TREAT-B (0.883; 95% CI 0.790-0.976; Sen. 85.3%; Sp. 70.3%) was substantially higher than the AUROC of the AASLD criteria (0.722; 95% CI 0. 0.566-0.878; Sen. 74.4%; Sp. 69.8%); and lower than the AUROC of the EASL criteria (0.952; 95% CI 0.790-0.976.
 Conclusion: The TREAT-B score was effective at identifying HBV-infected patients who should receive antiviral treatment.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
